The gold standard for treating the symptoms of PD is levodopa (L-dopa); however, within 3 to 5 years of treatment, approximately 50% of patients develop tolerance that necessitates higher doses taken more frequently and experience L-dopa induced dyskinesia (LID), which manifests as abnormal involuntary body motions that can interfere with the patient’s daily life.

PolyCore’s lead compound, PCT-3012, is a novel small molecule drug which has a significantly differentiated mechanism of action designed to modify how L-dopa works, rather than negating its effects, to improve motor symptoms without the development of tolerance, dyskinesia or impulsive behaviors.